Dr. Agarwal on the STAMPEDE and LATITUDE Trials for Prostate Cancer
Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the STAMPEDE and LATITUDE trials for patients with prostate cancer.
Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the STAMPEDE and LATITUDE trials for patients with prostate cancer.
The phase III STAMPEDE and LATITUDE trials have changed the standard of care for patients with newly diagnosed metastatic hormone-sensitive prostate cancer, states Agarwal.
Both trials combined abiraterone acetate (Zytiga) plus prednisone plus standard androgen deprivation therapy, explains Agarwal. Given the data from the trial, abiraterone plus prednisone is the new standard of care for the patient population.
